Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product?
The drugmaker badly needs more clinical wins.
Overview
Novo Nordisk's (NYSE:NVO) semaglutide, sold under the brand names Wegovy and Ozempic, is one of the world's best-selling compounds. Not that this has allowed the company to perform in line with broader equities over the past two years. The pharmaceutical giant has lost a little over 60% of its value over this period. Can Novo Nordisk bounce back?
That largely depends on the company's ongoing clinical development, and one of its candidates in particular, zenagamtide, looks highly promising. Novo is developing zenagamtide for obesity and diabetes. Could this be the next billion-dollar medicine for the Denmark-based drugmaker in its core therapeutic area?
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.